Last Updated: November 16, 2026

Details for Patent: RE47350

« Back to Dashboard


Which drugs does patent RE47350 protect, and when does it expire?

Patent RE47350 protects VRAYLAR and is included in one NDA.

Protection for VRAYLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in thirty-three countries.

Summary for Patent: RE47350
Title:Pharmaceutical formulations containing dopamine receptor ligands
Abstract:The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
Inventor(s):Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry
Assignee: Richter Gedeon Nyrt
Application Number:US15/598,971
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE47350
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

United States Patent RE47350: Cariprazine Formulation Claims, Scope, Expiration and Patent Landscape

United States Patent RE47350 protects a low-water-activity solid oral formulation of cariprazine for treating schizophrenia, bipolar disorder, acute mania and depression. The patent does not broadly claim cariprazine as a molecule. Its enforceable scope depends on a combination of formulation composition, dose, dissolution, pH and pharmacokinetic results.

The patent is strategically important because the claims can reach a generic product only if the product uses the claimed excipient architecture and produces the specified in vivo profile. The principal commercial product associated with the patent is Vraylar, marketed by AbbVie and containing cariprazine hydrochloride.

What drug and formulation does United States Patent RE47350 protect?

RE47350 covers pharmaceutical formulations containing trans-cariprazine, formally identified in the claims as:

trans-1-{4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl}-3,3-dimethylurea

The active ingredient is commonly known as cariprazine. Commercial cariprazine is generally supplied as the hydrochloride salt.

The patent claims a solid oral formulation that must satisfy all of the following conditions:

Required feature Claim limitation
Therapeutic use Schizophrenia, bipolar disorder, acute mania or depression
Dosage form Solid oral pharmaceutical formulation
Cariprazine amount About 0.05 mg to about 9 mg
Excipient Pregelatinized starch, mannitol, anhydrous calcium hydrogen phosphate, or a mixture
Plasma exposure Mean Cmax below about 26.3 ng/mL
Total exposure Mean AUC0-∞ above about 2 ng·hr/mL
Absorption timing Mean Tmax about 3 hours or longer
Dissolution More than 80% within about 60 minutes
Formulation pH About 9.0 to about 12.0

The claim is therefore a combination claim. A product that contains cariprazine but lacks the specified excipient, dissolution rate, pH or pharmacokinetic profile would not fall within claim 1 based on the claim language supplied.

How broad is independent claim 1 of RE47350?

Claim 1 is a method-of-treatment claim with formulation limitations. It requires administration to a patient, rather than merely making or selling a tablet.

Its breadth comes from four sources:

  1. It covers four psychiatric conditions.
  2. It covers a broad stated dose range of approximately 0.05 mg to 9 mg.
  3. It permits any of three named low-water-activity excipients or mixtures.
  4. It defines the formulation partly by measured clinical and dissolution characteristics.

Its principal limitation is that every recited requirement must be met. The claim does not expressly require a particular tablet weight, manufacturing process, crystalline form, coating, capsule shell or inactive-ingredient concentration.

Treatment indication scope

The indication language covers:

  • schizophrenia;
  • bipolar disorder;
  • acute mania; and
  • depression.

The claim does not appear limited to a particular disease severity, patient age, treatment line or titration schedule. The method must still involve a patient in need of treatment and administration of the claimed formulation.

A product approved only for an indication outside the listed conditions would present a different method-of-use analysis. A product labeled for one of the listed conditions would create a more direct infringement risk if its formulation also satisfied the physical and pharmacokinetic limitations.

Formulation scope

The excipient limitation is central. Claim 1 identifies:

  • pregelatinized starch;
  • mannitol;
  • anhydrous calcium hydrogen phosphate; or
  • mixtures of those materials.

The language does not require that these excipients be the only excipients. A formulation could potentially contain additional binders, lubricants, disintegrants, coatings or other inactive ingredients while remaining within the claim, provided the claimed excipient and performance limitations are satisfied.

The phrase “low water activity” supplies a functional formulation concept, while the Markush group identifies the expressly claimed excipient alternatives. Water activity is distinct from water content. A tablet with low total moisture is not necessarily within the claim unless the claimed excipient and remaining limitations are also met.

What do claims 2 through 10 add?

Claims 2 through 10 narrow claim 1 by specifying individual doses, pharmacokinetic thresholds or excipients.

Claim Dose Additional limitation
2 1.5 mg Mean Cmax below about 2.7 ng/mL; Tmax at least about 3 hours
3 3 mg Mean Cmax below about 5.3 ng/mL; Tmax at least about 3 hours
4 4.5 mg Mean Cmax below about 7.9 ng/mL; Tmax at least about 3 hours
5 6 mg Mean Cmax below about 10.5 ng/mL; Tmax at least about 3 hours
6 9 mg Mean AUC0-∞ above about 180 ng·hr/mL; Tmax at least about 3 hours
7 0.5 mg Mean Cmax below about 0.9 ng/mL; Tmax at least about 3 hours
8 Any claim 1 dose Excipient comprises pregelatinized starch
9 Any claim 1 dose Excipient comprises mannitol
10 Any claim 1 dose Excipient comprises anhydrous calcium hydrogen phosphate

Claims 2 through 7 are dose-specific pharmacokinetic claims. They are not simple dosage claims because each includes a plasma-profile requirement. Claims 8 through 10 isolate the three principal excipient alternatives and may be easier to test analytically than the broader pharmacokinetic limitations.

What is the patent expiration date for RE47350?

RE47350 is a reissue patent. A reissue does not ordinarily receive a new 20-year patent term. Its term is tied to the underlying original patent and earliest effective nonprovisional priority date.

The relevant commercial term is expected to run through December 2029, subject to any applicable patent-term adjustment or extension recorded for the underlying patent. The patent was issued as a reissue on May 7, 2019. Its reissue status does not by itself extend exclusivity beyond the original patent term.

Event Date or period
Earliest relevant priority period December 2009
Original patent family US 8,598,233
Reissue patent US RE47,350
Reissue grant May 7, 2019
Expected nominal expiration December 2029

The critical diligence point is that the reissue number should not be treated as a separate 20-year term. Patent-term adjustment, terminal disclaimers and the official USPTO term calculation control the final enforceable date.

What is the Orange Book status of cariprazine and Vraylar?

Vraylar is FDA-approved cariprazine hydrochloride. The FDA approved Vraylar for schizophrenia and manic or mixed episodes associated with bipolar I disorder in 2015, and later approved it for depressive episodes associated with bipolar I disorder. The FDA label identifies Vraylar as capsules containing cariprazine hydrochloride in multiple strengths. [1]

The FDA Orange Book has listed patents associated with Vraylar and cariprazine formulations, including the original patent family associated with RE47350 and later cariprazine patents. Orange Book listing status must be evaluated patent by patent because listed patents may cover different subjects, including:

  • drug substance;
  • formulation;
  • dosing regimen;
  • method of treatment; and
  • other product-specific characteristics.

RE47350 is most relevant to formulation and pharmacokinetic overlap. A generic applicant would need to assess whether its proposed formulation falls within the listed patent claims, not merely whether it contains the same active ingredient.

What Paragraph IV challenges could apply to RE47350?

A generic applicant could file a Paragraph IV certification asserting that RE47350 is invalid, unenforceable or not infringed. The principal technical positions would likely involve the following issues:

Lack of infringement

A challenger could design around one or more claim elements by using:

  • an excipient outside the three named classes;
  • a different water-activity strategy;
  • a formulation pH below 9 or above 12;
  • dissolution of 80% or less at 60 minutes;
  • a plasma profile outside the specified thresholds; or
  • a different dosage form.

The difficulty is that some limitations are product characteristics, while others are patient pharmacokinetic results. A formulation may produce different Cmax or Tmax values depending on food, patient population, assay method, dose strength and study design.

Claim construction

The parties could dispute the meaning of:

  • “about” in the dose, pH, dissolution and pharmacokinetic ranges;
  • “mean” Cmax, AUC and Tmax;
  • “within about the first 60 minutes”;
  • “following administration”;
  • “low water activity”; and
  • “pharmaceutically acceptable salt thereof.”

These terms create potential infringement and validity disputes concerning measurement conditions and acceptable analytical variation.

Written description and enablement

The patent claims multiple doses, excipient combinations and pharmacokinetic outcomes. A challenger could argue that the specification does not support the full breadth of the claimed ranges or all combinations of dose, excipient and performance limitations.

Obviousness

The core obviousness question would be whether a skilled formulator would have combined cariprazine with one of the specified low-water-activity excipients, selected the claimed pH and dissolution profile, and achieved the claimed plasma exposure. The pharmacokinetic limitations may strengthen patentability if they reflect an unexpected relationship between formulation design and exposure.

How strong is the RE47350 patent estate?

RE47350 has moderate-to-strong commercial relevance but a narrower infringement perimeter than a basic compound patent.

Strength factor Assessment
Active ingredient Narrowed to cariprazine, but cariprazine is commercially important
Dosage form Limited to solid oral formulations
Excipient coverage Focused on three named low-water-activity excipients
PK limitations Creates a meaningful barrier but introduces measurement disputes
Dissolution limitation Testable and potentially useful for infringement analysis
pH limitation Provides a clear design-around parameter
Treatment claims Can support infringement where labeling directs use
Manufacturing coverage No express process claim in the supplied claims
Composition coverage No standalone composition claim in the supplied claims

The patent is stronger against a generic that reproduces the reference product’s formulation and pharmacokinetic behavior. It is weaker against a generic that uses a different excipient system or intentionally changes pH and release characteristics.

What manufacturing and formulation barriers does RE47350 create?

The patent does not claim a manufacturing process, but its performance limitations can indirectly constrain formulation development.

A competing manufacturer would need to control:

  • excipient water activity;
  • tablet or capsule microenvironment pH;
  • dissolution rate;
  • particle size and blend uniformity;
  • salt form and active-ingredient loading;
  • storage moisture exposure; and
  • dose-dependent plasma exposure.

Cariprazine is a highly active compound administered at low milligram doses. Small changes in content uniformity, particle properties and dissolution behavior can affect exposure. That makes formulation design and bioequivalence testing material to both regulatory and patent strategy.

A design-around must be evaluated experimentally. Simply changing a trade name, capsule color or tablet size would not avoid the patent if all claim limitations remain present.

Which companies are challenging Vraylar patents?

Publicly reported generic activity concerning Vraylar has involved ANDA applicants and Hatch-Waxman litigation directed at AbbVie’s cariprazine patent portfolio. The relevant analysis should separate:

  1. litigation involving RE47350 specifically;
  2. litigation involving other Orange Book-listed cariprazine patents;
  3. Paragraph IV certifications that did not result in a filed action; and
  4. settlement agreements that may establish a future generic entry date.

A Paragraph IV certification does not itself establish invalidity or noninfringement. The commercial result depends on the filed patent claims, court rulings, settlement terms and FDA approval status.

What generic launch scenarios exist for cariprazine?

The main launch scenarios are:

Scenario Commercial effect
RE47350 remains enforceable through nominal expiration Generic formulation must avoid the claims or await patent expiry
Generic wins noninfringement Entry may occur after FDA approval and resolution of other listed patents
Generic wins invalidity Earlier launch becomes possible, subject to remaining patents
Settlement permits licensed entry Entry occurs on the agreed date and terms
Product avoids RE47350 but infringes another listed patent RE47350 does not eliminate overall launch risk
Label omits a patented indication Risk may shift to induced-infringement and skinny-label issues

A generic applicant must clear the entire Orange Book portfolio, not only RE47350. A noninfringing formulation under RE47350 can still face separate substance, method-of-use or formulation patents.

How does RE47350 compare with a compound patent?

A compound patent generally protects the active molecule against broad use and formulation substitutions. RE47350 is narrower because it requires a defined formulation and clinical-performance profile.

Issue Compound patent RE47350
Primary subject Cariprazine molecule Cariprazine solid oral formulation and use
Design-around difficulty High Moderate
Dependence on clinical testing Usually limited High
Formulation specificity Low High
Manufacturing-process coverage Not necessarily Not in supplied claims
Infringement proof Chemical identity and use Formulation testing plus PK and dissolution evidence
Generic vulnerability Lower Higher if alternative formulation is feasible

RE47350 is most valuable as part of a layered portfolio. Its commercial effect is greater when combined with other patents covering cariprazine, dosing regimens, formulations or approved uses.

Key Takeaways

  • RE47350 claims treatment with a solid oral cariprazine formulation, not cariprazine as a molecule.
  • Claim 1 requires a named low-water-activity excipient, pH of about 9 to 12, rapid dissolution and defined plasma exposure.
  • Claims 2 through 7 add dose-specific Cmax or AUC thresholds from 0.5 mg through 9 mg.
  • Claims 8 through 10 separately cover pregelatinized starch, mannitol and anhydrous calcium hydrogen phosphate.
  • The expected nominal patent term runs through December 2029, subject to the official term calculation.
  • The principal generic strategy is formulation design-around, especially through excipient selection, pH control and dissolution engineering.
  • Orange Book and litigation analysis must include the full Vraylar patent portfolio, not RE47350 alone.
  • The patent is commercially meaningful but narrower and more measurement-dependent than a cariprazine compound patent.

FAQs About US Patent RE47350 and Cariprazine

Does RE47350 cover all cariprazine tablets?

No. It covers only solid oral formulations that satisfy the claimed excipient, pH, dissolution and pharmacokinetic requirements and are used for a listed condition.

Can a generic use cariprazine without infringing RE47350?

Yes, potentially. A generic may avoid infringement by using a different excipient system, pH, dissolution profile or formulation that does not produce the claimed pharmacokinetic results. Other cariprazine patents may still block launch.

Does RE47350 cover cariprazine hydrochloride?

The claims cover cariprazine and pharmaceutically acceptable salts. Cariprazine hydrochloride is within the salt language if the remaining limitations are satisfied.

Is a Paragraph IV challenge to RE47350 automatically a generic launch approval?

No. FDA approval, patent litigation, other Orange Book-listed patents and any settlement agreement independently affect launch timing.

Why are the Cmax and Tmax limits important?

They convert the patent from a simple ingredient-and-excipient claim into a performance-based claim. A generic formulation can avoid the claim only if its measured clinical profile falls outside the relevant thresholds or another claim element is absent.

References

  1. U.S. Food and Drug Administration. (2024). Vraylar (cariprazine) prescribing information.
  2. U.S. Patent and Trademark Office. (2019). United States Patent RE47,350: Pharmaceutical compositions comprising cariprazine.
  3. U.S. Patent and Trademark Office. (2013). United States Patent 8,598,233: Pharmaceutical compositions comprising cariprazine.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
  5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent RE47350

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-005 Dec 18, 2025 RX Yes No RE47350*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-006 Dec 18, 2025 RX Yes No RE47350*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 RX Yes Yes RE47350*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE47350

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2975 ⤷  Start Trial
Australia 2009270823 ⤷  Start Trial
Brazil PI0916241 ⤷  Start Trial
Canada 2730287 ⤷  Start Trial
Chile 2011000091 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.